- Levitee (LVT) has partnered with Canntab Therapeutics (PILL) to provide opioid alternatives
- Pursuant to the companies’ service agreement, Levitee will inform customers in Alberta and B.C. about Canntab products as opioid alternatives
- Levitee’s clinics and pharmacies have hosted over 35,000 patient visits over the last year
- Canntab is a Canadian phytopharmaceutical company focused on manufacturing and distributing hard-pill cannabinoid formulations
- Levitee operates in the integrative wellness space with a focus on psychedelic medicines and therapies
- Canntab Therapeutics (PILL) is up by 2.86 per cent trading at $0.72 per share
- Levitee Labs (LVT) is up by 7.14 per cent trading at $0.30 per share
Levitee (LVT) has partnered with Canntab Therapeutics (PILL) to provide opioid alternatives.
Pursuant to the companies’ service agreement, Levitee will inform customers in Alberta and B.C. about Canntab products as alternatives for pain management, addiction and other disorders.
Levitee owns five addiction clinics and three specialized pharmacies with over 35,000 patient visits in the last 12 months.
The partnership is anticipated to enhance patient care and drive additional revenue.
“We share a vision with Canntab to play a meaningful role in flattening the curve of the opioid crisis in Canada by tapering use of addictive painkillers through the substitution of viable alternatives, which can include cannabinoids like CBD and THC and combination thereof,” said Noha ElSayed, Executive Director of Levitee Clinics and Levitee Pharmacies, Alberta Region.
“Notwithstanding the lack of clinical trials for product-specific uses,” she added, “cannabinoids have shown great promise to provide patients relief for multiple indications in which we specialize.”
“Our hard pill formulations are superior to all other medical CBD and THC delivery systems and designed to produce both immediate and durable relief for acute and chronic pain,” stated Richard Goldstein, Canntab’s Co-Founder and Chief Financial Officer.
“Furthermore,” he added, “our manufacturing capacities are not limited. In the future, I see the potential for our production expertise to be extremely synergistic with Levitee’s compounding capabilities to provide a diverse portfolio of therapeutics, including those in the psychedelics space when regulations allow.”
Canntab is a Canadian phytopharmaceutical company focused on manufacturing and distributing hard-pill cannabinoid formulations.
Levitee operates in the integrative wellness space with a focus on psychedelic medicines and therapies.
Canntab Therapeutics (PILL) is up by 2.86 per cent trading at $0.72 per share as of 11:47 am EST.
Levitee Labs (LVT) is up by 7.14 per cent trading at $0.30 per share as of 11:53 am EST.
